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Background/Purpose: A signiﬁcant increase in the prescribing of nonbenzodiazepine hypnotic agents (z-
hypnotics) has been noticed in the past decade. Several safety concerns have emerged after the excessive
use of z-hypnotics. This study aims to characterize the z-hypnotics users with a focus on those with
overlapping duration of z-hypnotics supply by using Taiwan's National Health Insurance Research
Database.
Methods: Incident z-hypnotic users who received at least one z-hypnotic prescription from outpatient
settings during 2001e2010 were identiﬁed and classiﬁed into three groups: duplicated users (those who
received multiple z-hypnotic prescriptions on the same day), suspected duplicated users (those who
received multiple z-hypnotic prescriptions with 7þ days of overlapping supply), and nonduplicated
users. We examined the demographic proﬁles of these z-hypnotic users as well as z-hypnotics pre-
scriptions (duration, daily consumption, and characteristics of providers).
Results: We identiﬁed 242,412 incident users of z-hypnotics with 2.4 million z-hypnotic prescriptions
during the 10-year study. Almost 20% of them were duplicated (n ¼ 29,948) and suspected duplicated
users (n ¼ 16,899). Duplicated and suspected duplicated users were more likely to be male and in their
old age compared to the nonduplicated users. Approximately half of the suspected duplicated users
(51.8%) and nonduplicated users (47.0%) received their z-hypnotic prescriptions from primary care clinics
while duplicated users received their z-hypnotic prescriptions from metropolitan hospitals (29.9%) and
academic medical center (26.2%). Duplicated z-hypnotic users were more likely to receive more days'
supply and higher daily dose of z-hypnotics. Up to 31.0% of duplicated z-hypnotics users received > 1
deﬁned daily dose/day if adding all prescriptions they received within 1 day.
Conclusion: Duplicated z-hypnotic users were more likely to receive prescriptions with long duration
and high daily dose. Healthcare professionals and policy makers are recommended to put more efforts
into dealing with this urgent drug safety issue.
Copyright © 2016, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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A signiﬁcant increase in the prescribing of nonbenzodiazepine
hypnotic agents, the so-called z-hypnotics, has been noticed in the
past decade.1e4 Compared to benzodiazepines (BZDs), z-hypnotics
are considered as safer alternatives for insomnia due to their
improved pharmacokinetic proﬁle.5 However, several safety con-
cerns have emerged after the tremendous use of z-hypnotics. Somelished by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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hypnotics, particularly long-term use in the elderly, which may
result in adverse events.1,6 Another major safety issue is the doctor-
shopping behaviors among insomnia patients and accompanying
dependency of z-hypnotics.7 More empirical data regarding the
quality of z-hypnotics prescriptions and characteristics of potential
z-hypnotic-dependent users will help clinicians and policy-makers
to identify hot-spots for rational use of z-hypnotics. Using Taiwan's
National Health Insurance research database (NHIRD), this study
examined the demographic proﬁles of z-hypnotic users as well as z-
hypnotic prescriptions (duration and daily consumption) they
received.
Methods
Data source
This retrospective cohort study used 12 years of data
(1999e2010) from the National Health Insurance Research Data-
base (NHIRD), a nationwide claims database from Taiwan's
mandatory National Health Insurance program. The NHIRD con-
tains anonymous eligibility and enrollment information, as well as
claims for visits, procedures, and prescription medications for >
99% of the entire population (23million) in Taiwan.8 Two subsets of
the NHIRD, the Longitudinal Health Insurance Database (LHID)
2000 and LHID 2005, which contains a total of two million bene-
ﬁciaries randomly selected from the NHIRD were used as our
original cohort. The details of LHIDs and NHIRD were described in
the NHI website and in our previous publication.1,9
Study participants
Patients who received a prescription of z-hypnotics (zolpidem,
zopiclone, or zaleplon) from an outpatient setting from January 1,
2001 to December 31, 2010 were identiﬁed as our study partici-
pants. The ﬁrst prescription date of z-hypnotics was deﬁned as the
cohort entry date. To be eligible for the deﬁnition of incident z-
hypnotics users, those who received z-hypnotics 1 year prior to the
cohort entry date were excluded. The characteristics of z-hypnotic
users were collected at the cohort entry date.
All z-hypnotic prescriptions received by our study participants
in the outpatient setting between the cohort entry date and
December 31, 2010 were retrieved from the LHID. Incident z-hyp-
notic users were then categorized into three groups based on how
they received their z-hypnotic prescriptions. Those who ever
received z-hypnotics on the same day were deﬁned as the dupli-
cated users while those who ever received z-hypnotics with 
7 days of overlapping supply were deﬁned as suspected duplicated
users. For example, if a patient receives two prescriptions (both
were 28-days of supply of z-hypnotic) on January 14 and January
26, respectively, then they are deﬁned as the suspected duplicated
user. Other z-hypnotic users were deﬁned as nonduplicated users.
Measurements and statistical analysis
Demographics of z-hypnotic users including age and sex were
collected. Providers' characteristics, including prescribing physi-
cians and medical facilities, were further examined. Prescribing
physicians were grouped by their specialties (e.g., psychiatry).
Medical facilities were characterized by accreditation levels: med-
ical center, metropolitan hospital, local community hospital, and
clinic. Several measures, including prescription duration, daily pills,
and daily dosage, were used to quantify the use of z-hypnotics
among the three types of z-hypnotics users. The daily dosage of z-
hypnotics was calculated by number of pills taken and deﬁned dailydose (DDD) and presented by per-prescription as well as per-
patient. The numbers of z-hypnotics prescriptions received within
a day by duplicated z-hypnotics users were also investigated.
All data are expressed as number with percentage or meanwith
standard deviation and compared using analysis of variance
(ANOVA) or Chi-square test. The analyses were performed with
SAS, version 9.2 (SAS Institute, Cary, NC, USA).
Results
We identiﬁed 242,412 z-hypnotic users and 2.4 million z-hyp-
notic prescriptions received by them over the 10 years of the study
period. The characteristics of z-hypnotic users are shown in Table 1.
Nearly one-ﬁfth of z-hypnotic users (n ¼ 46,847) had received at
least one duplicated or suspected duplicated prescriptions during
the study period. The proportion of men in duplicated (41.2%) and
suspected duplicated z-hypnotic users (41.0%) were signiﬁcantly
higher than nonduplicated users (p < 0.01). Approximately one-
third (31.6%) of duplicated and one-fourth (26.8%) of suspected
duplicated z-hypnotic users were elderly.
Duplicated z-hypnotic users received higher number of z-hyp-
notics prescriptions (36.1 prescriptions/patient in average)
compared to the other two groups. Duplicated z-hypnotic users
were more likely to receive their z-hypnotic prescriptions from
metropolitan hospitals (29.9%) and medical centers (26.2%),
whereas other users mostly received their z-hypnotics from clinics
(47.0% in nonduplicated and 51.8% in suspected duplicated z-hyp-
notic users). Duplicated z-hypnotic users were more likely to
receive their z-hypnotics prescriptions from neurology specialist
but less likely from physicians in internal medicine and family
medicine compared to the other two groups (Table 2).
Approximately 90% of duplicated z-hypnotics users received a
prescription of > 7 days of supply (89.0% of 8e30 days and 0.5% of >
30 days). The daily z-hypnotic consumption was higher among
duplicated users. Nearly one-sixth (15.2%) of them received > 1
DDD/d per prescription (vs. 6.8% of nonduplicated and 12.9% of
suspected duplicated z-hypnotic users). Up to 31.0% of duplicated z-
hypnotics users received > 1 DDD/d if adding all prescriptions they
received within 1 day (Table 3).
Approximately 60% (56.9%) and 40% (42.4%) of duplicated z-
hypnotic users received two or three prescriptions within a day.
However, we found that very few patients receivedmore than three
z-hypnotics prescriptions within 1 day (Table 4).
Discussion
This study is the ﬁrst to investigate the characteristics of
duplicated z-hypnotics users and their utilization patterns of z-
hypnotics over the past decade in Taiwan.We found that duplicated
z-hypnotics users were more likely to be male and of older age and
to receive their z-hypnotic prescriptions from metropolitan hos-
pitals and medical centers. In addition, duplicated z-hypnotic users
were more likely to receive prescriptions with long duration and
high daily dose compared to their nonduplicated counterparts.
Recently, potential drug abuse resulting frommultiple providers
and drug-driven shopping behavior has become a critical issue in
many countries.10e12 Nevertheless, previous studies have focused
on opioids but not in sedatives such as BZD and z-hypnotics.
Identifying patients who have high possibility of duplicated z-
hypnotics use can help to reduce the risks of z-hypnotic misuse and
associated adverse events.
Under the universal healthcare insurance provided by Taiwan's
National Health Insurance program, patients in Taiwan have very
high accessibility to healthcare services with relatively low ﬁnan-
cial and referral barriers. It was estimated that 17.3% of outpatients
Table 1
Baseline characteristics of z-hypnotic users.
Nonduplicated users Suspected duplicated users Duplicated users p *
Patients number 195,565 16,899 29,948
Sex
Male 77,103 (39.5) 6,928 (41.0) 12,352 (41.2) < 0.01
Female 118,104 (60.5) 9,955 (59.0) 17,574 (58.7)
Age (y) 47.8 ± 17.3 51.9 ± 17.0 55.0 ± 16.2 < 0.01
< 18 2,774 (1.4) 92 (0.5) 102 (0.3) < 0.01
18e39 64,621 (33.0) 4,208 (24.9) 5,497 (18.4)
40e64 90,427 (46.2) 8,075 (47.8) 14,902 (49.8)
65e79 30,191 (15.4) 3,700 (21.9) 7,837 (26.2)
 80 7,552 (3.9) 824 (4.9) 1,610 (5.4)
Data are presented as n (%) or mean ± standard deviation.
* Analysis of variance or Chi-square test.
Table 2
Characteristics of z-hypnotics prescriptions received by non-, suspected-, and duplicated z-hypnotic users.
Nonduplicated users
(n ¼ 195,565)
Suspected duplicated users
(n ¼ 16,899)
Duplicated users
(n ¼ 29,948)
p *
Prescriptions number 905,935 445,137 1,081,017
Prescription/patient 4.6 26.3 36.1
Setting
Clinic 425,843 (47.0) 230,696 (51.8) 318,117 (29.4) < 0.01
Local community hospital 151,053 (16.7) 75,583 (17.0) 156,395 (14.5)
Metropolitan hospital 192,067 (21.2) 82,362 (18.5) 323,288 (29.9)
Medical center 136,972 (15.1) 56,496 (12.7) 283,217 (26.2)
Specialty
Psychiatry 220,529 (24.3) 111,833 (25.1) 266,019 (24.6) < 0.01
Family medicine 160,791 (17.7) 91,276 (20.5) 150,514 (13.9)
Interior medicine 146,038 (16.1) 76,328 (17.1) 142,120 (13.1)
Neurology 55,692 (6.1) 25,030 (5.6) 101,255 (9.4)
Duration (d) 2.5 ± 0.7 2.7 ± 0.6 2.9 ± 0.5 < 0.01
< 3 135,431 (14.9) 31,884 (7.2) 41,372 (3.8) < 0.01
3e7 175,603 (19.4) 50,477 (11.3) 73,013 (6.8)
8e30 593,068 (65.5) 360,911 (81.1) 961,734 (89.0)
> 30 1,833 (0.2) 1,865 (0.4) 4,898 (0.5)
Data are presented as n (%) or mean ± standard deviation.
* Analysis of variance or Chi-square test.
Table 3
Comparison of daily consumption of z-hypnotics received by non-, suspected-, and duplicated z-hypnotic users.
Nonduplicated users
(n ¼ 195,565)
Suspected duplicated users (n ¼ 16,899) Duplicated users
(n ¼ 29,948)
p *
Per prescription Per prescription Per prescription Per day
Daily use (pills) 2.0 ± 0.6 2.1 ± 0.8 2.2 ± 0.8 2.6 ± 1.1 < 0.01
< 0.5 126,250 (13.9) 48,647 (10.9) 128,333 (11.9) 68,171 (8.0) < 0.01
0.5e1 717,182 (79.2) 338,994 (76.2) 787,717 (72.9) 518,213 (60.9)
1e1.5 12,989 (1.4) 11,002 (2.5) 33,047 (3.1) 34,637 (4.1)
1.5e2 43,744 (4.8) 43,482 (9.8) 121,219 (11.2) 148,283 (17.4)
> 2 5770 (0.6) 3062 (0.7) 10,701 (1.0) 80,981 (9.4)
Daily dosage < 0.01
 1 DDD 843,939 (93.2) 387,870 (87.1) 916,614 (84.8) 587,022 (69.0)
> 1 DDD 61,996 (6.8) 57,267 (12.9) 1,644,403 (15.2) 263,263 (31.0)
Data are presented as n (%) or mean ± standard deviation.
* Analysis of variance or Chi-square test.
DDD ¼ deﬁned daily dose.
Table 4
Frequency of duplicated prescriptions within a day.
Prescription number Patient number (%)
2 90,986 (56.9)
3 67,795 (42.4)
4 843 (0.5)
5 108 (0.1)
6e9 229 (0.1)
10þ 2 (0.0)
Total 159,963
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Taiwan.13 This phenomenon is particularly prevalent in older pa-
tients, who usually have multiple comorbidities and tend to seek
treatments from different specialties.14 Our study also found that
12.3% of our study participants received more than two z-hypnotic
prescriptions within a day. These duplicated z-hypnotic users were
more likely to be older, which is consistent with ﬁndings from a
study done byWu et al15 that there is an increasing risk for multiple
physician visits associated with age. The risk of duplicated z-hyp-
notics use in the elderly could worsen if a patient repeatedly
P.-H. Hsieh et al. / Journal of Clinical Gerontology & Geriatrics 7 (2016) 60e63 63complains of sleep problems when visiting different physicians in
different medical institutions. A comprehensive review of medi-
cation use of a patient, especially an older one, is warranted to
reduce such risk.
Our study also found signiﬁcant variations in the distribution of
sex and age among different types of z-hypnotic users. Women
accounted for the majority of the entire z-hypnotic users; that is,
women were more likely to receive z-hypnotics compared to
men.2,16,17 However, an increasing proportion of men was found
among patients with duplicated z-hypnotic use. This ﬁnding is
similar with a Norwegian population-based study, which suggested
that inappropriate use of z-hypnotic and anxiolytic BZD in the
elderly, deﬁned as long-term use of z-hypnotics for > 30 weeks or
use of z-hypnotics with high dosage, is more prevalent in men.16 By
contrast, another study conducted in general Danish elderly re-
ported that women are more likely to receive long-term use of z-
hypnotic, but the association become insigniﬁcant after limiting the
analysis to z-hypnotic users only. The authors concluded that
women are more likely to start z-hypnotics, but there is no differ-
ence in terms of long-term use of z-hypnotic between men and
women.6
According to the results of our previous study, the proportion of
z-hypnotic prescriptions from clinics and physicians not special-
izing in psychiatry were increased recently, raising the awareness
of the easier access of z-hypnotics obtainment in Taiwan.1 However,
we found that patients with duplicated prescriptions were more
likely to receive their prescriptions from physicians in psychiatry
and tertiary-care hospitals. Patients' own comorbidities may be one
of inﬂuential factors for these inconsistent results. For some dis-
eases, combined use of psychotropic medications with lower level
are recommended for reducing the risk of adverse drug effects. One
cross-sectional study showed that psychotropic polypharmacy,
which is deﬁned as simultaneous use of two or more anxiolytic
hypnotics, accounted for almost 70% of all person-days of
anxiolytic-hypnotic use in Taiwan.3 In addition, patients with
mental diseases may be one of the reasons inducing multiple
opinion-seeking or drug-driven visits. According to the study done
by Norton et al,18 doctor-shopping was associated with higher rates
of mental illness. A study by Huang and Lai19 also reported a sig-
niﬁcant association of concomitant anxiety or depression with
higher consumption of hypnotics among older insomniacs. In-
dications and concomitant medication use among z-hypnotics
users were beyond the investigation of this study and more
research is warranted.
We found that duplicated z-hypnotic users were more likely to
have higher and longer consumption of z-hypnotic compared to
nonduplicated users. This ﬁnding was consistent with another
Taiwanese study done by Lu et al,7 which reported 736.49 DDD in
patients with doctor-shopping behavior (deﬁned as duplicated z-
hypnotics with  1 overlapping day of supply from different phy-
sicians) and 160.63 DDD in thosewithout during a 2-year follow-up
period. Lu et al7 also reported that only 20% of total z-hypnotics
DDD among doctor-shopping patients originated from duplicated
prescriptions. They concluded the potential tolerance of z-hyp-
notics triggers the needs for chronic and high-amount use. Our
study further provided the details of total consumption per day and
found that up to 31.0% of duplicated z-hypnotics users received > 1
DDD/d if adding all prescriptions they received within 1 day.
Our study adds to the knowledge regarding the characteristics of
duplicated z-hypnotics users and their utilization patterns of z-
hypnotics. Nevertheless, there were several limitations in this
study. First, as with all observational studies based on claim data-
bases, we were unable to include social and behavior factorsassociated with duplicated z-hypnotic users. Second, the total
amount of z-hypnotic use by our study participants may be
underestimated as patients may receive their z-hypnotics from
other sources.
In summary, duplicated z-hypnotic users were more likely to
receive prescriptions with long duration and high daily dose
compared to their nonduplicated counterparts. Healthcare pro-
fessionals and policy makers are recommended to invest more
effort in dealing with this urgent drug safety issue.Conﬂicts of interest
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